Gene study reveals how MS drug works in chinese patients

NCT ID NCT04410965

First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 26 times

Summary

This study looked at how a specific gene change (ABCG2 mutation) affects the amount of the MS drug teriflunomide in the body and its safety. 82 Chinese adults with relapsing multiple sclerosis took the drug once daily for 24 weeks. Researchers measured drug levels and tracked side effects to understand the gene's role.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Investigational Site Number

    China, China

Conditions

Explore the condition pages connected to this study.